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ABSTRACT
We have studied the erythroid-specific promoter of the human gene
coding for Porphobilinogen Deaminase (PBGD) by DNaseI footprinting, gel
retardation and methylation interference assays. We show that this
promoter, which is inducible during MEL cell differentiation, contains three
binding sites for the erythroid-specific factor NF-E1 and one site for a
second erythroid-specific factor, which we name NF-E2. NF-E1 is a factor
that also binds the promoter and the enhancer (present in the 3' flanking
region) of the human P-globin gene. NF-E2 has not yet been described and
although it binds to a sequence containing the Apl consensus, it appears to
be different from Apl.
INTRODUCTION
The red cell lineage is a good model to study the mechanisms which
regulate the co-ordinated appearance of specific gene products during
cellular differentiation. In particular, differentiation of erythroid cells
leads to the production of large amounts of hemoglobin, a molecule which is
the direct and indirect product of several sets of genes. The two pairs of
globin chains, which differ according to the developmental stage of the
organism, are encoded by two sets of genes grouped into two clusters: the a-
like globin cluster (on human chromosome 16) and the f-like cluster (on
human chromosome 11) (for review, see 1). These globin chains are linked to
four heme molecules whose synthesis is catalyzed by the enzymes of the heme
biosynthetic pathway (for review, see 2).
Globin genes are transcribed exclusively in the red cell lineage,
whereas the genes of the heme biosynthetic pathway are expressed in all
cells, as heme is also the prosthetic group of cytochromes. The activity of
all the enzymes of this pathway increases during erythroid differentiation
and recent reports have shown that the genes encoding three of these enzymes
are transcriptionally activated during this differentiation (3,4,5).
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However, the molecular basis of the co-ordinated induction of transcription
of globin genes and genes of the heme biosynthetic pathway is unknown.
The P-globin gene has been extensively studied and its regulatory
sequences have been defined (6-15). Among the genes of the heme
biosynthetic pathway, the human gene encoding Porphobilinogen Deaminase
[PBGD; porphobilinogen ammonia-lyase (polymerizing), EC 4-3-1-8] has been
described recently. This gene has two promoters, one housekeeping and one
erythroid-specific, which yield two different mRNAs having a specific first
exon and 13 common exons (16).
Further studies have shown that the human PBGD gene and a hybrid gene
containing the PBGD erythroid promoter (-714 to +78) fused to the Herpes
Simplex Virus thymidine kinase (HSVtk) coding sequence are correctly
expressed and activated when introduced into murine erythroleukemia (MEL)
cells which can be differentiated in vitro (Raich et al., submitted).
These results suggest that structural features within the PBGD
erythroid promoter are responsible for its transcriptional activation during
erythroid differentiation. In addition, preliminary expression experiments
in K562 cells indicate that a subfragment of the PBGD promoter, spanning
nucleotides -243 to +78, is able to direct transcription (at the same level
as the -714 to +78 fragment), while a drastic decrease in transcription is
observed when sequences downstream from -112 are further removed (V.
Mignotte et al., unpublished data). In MEL cells, the -243/+78 fragment
retains the ability to induce transcription during differentiation (N. Raich
et al., unpublished data). In this report, we show the analysis of the -
243/+78 fragment by the DNaseI footprinting and gel retardation techniques
to determine which sequences can bind nuclear factors from different cell
types in vitro and to compare its organization to that of the ,B-globin
promoter. We conclude that the PBGD promoter contains seven major binding
sites, four of which bind erythroid-specific factors. One of these factors
is common to the PBGD promoter, the f-globin promoter (15) and the fl-globin
3' enhancer (14); the second erythroid-specific factor has not been
described previously.
RESULTS
Analysis of the PBGD erythroid promoter by DNaseI footprintinq
A promoter fragment spanning nucleotides -243 to +78 relative to the
site of transcription initiation was analyzed for the binding of nuclear
factors by DNaseI footprinting assays. This fragment was specifically radio-
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labelled at either end, then incubated with crude nuclear extracts from non
erythroid (HeLa) or erythroid (K562, MEL) cells and digested with DNaseI.
The regions showing protection from DNaseI digestion (footprints) or
increased sensitivity are shown in Fig. 1.
A first footprint, covering the -180 region, is present only in K562
and MEL extracts; it is visible with small amounts of extract. A second
footprint (-160 region) can be seen with higher concentrations of HeLa and
MEL extracts; it only starts to appear with the highest concentration of
the K562 extract (Fig. IA, B) and can be clearly visualized at even higher
concentrations of K562 extract (not shown). This footprint is very labile,
i.e. it was not apparent in all assays for a given cell extract. A third
footprint (-130 region) is weak in all extracts and appears to be caused by
two adjacent binding activities (see below). A fourth footprint (-100
region) lies over a CAC consensus sequence and can be seen in all extracts
with low concentrations of protein. We do not observe a footprint on the
-85 region which contains a mutated CAAT box sequence. A fifth footprint
(-70 region) is present with K562 and MEL extracts (Fig. IA, B from 5,4g) but
not with HeLa extracts. It is surrounded by strong hypersensitive sites on
the coding strand. No clear footprint can be seen between -60 and the
transcription initiation site. However, a weak footprint centred on +45 is
observed on the coding strand in K562 and MEL extracts, on a long migration
of a gel identical to that of Figure 1A (not shown).
From these results we tentatively concluded that this promoter fragment
contains at least seven binding sites, three of which may be erythroid
specific.
Analysis of the sequences within the footprinted regions reveals the
three putative erythroid-specific binding sites (-180, -70 and +45 regions)
to contain the consensus motif C/A Py T/A ATC T/A Py which is present
multiple times in the P-globin enhancers and the promoter. This sequence was
shown to bind an erythroid-specific protein NF-E1 (14,15)and to compete for
these footprints (data not shown). The -160 region contains a CCAGTGAC
sequence which is analogous to a sequence found around -150 in the 0-globin
promoter, shown to be necessary for induction of the f-globin promoter in
MEL cells (12,15). This region of the PBGD promoter also contains an exact
match with the consensus sequence for Apl (TGACTCA) (17). Lastly, the CAC
consensus sequence from a-like globin genes is found in the sequence around
-100 in the PBGD promoter (16).
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Characterization of the trans-acting factors by mobility shift assays
To identify which individual proteins interact with each of the binding
sites, a number of oligonucleotides were used as probes or competitors in
gel retardation assays; each of the three putative erythroid-specific
sites, the -160 region, the -130 region and the CAC box. These were
compared together and with various other oligonucleotides: four
oligonucleotides from the f-globin 3' enhancer (A, B, C and D), four from
the fi-globin promoter (regions -200, -150, -120 and the CAC box region) and
five oligonucleotides binding known proteins, the a-globin CAAT box, an
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DNaseI footprinting analysis of t~PBGD erythroid -specific promoter.The -243 to +78 promoter fragment was P-aele either on the coding
strand (A) or on the non-coding strand (B), then incubated with either HeLa,
K562 or uninduced MEL nuclear extracts and treated with DNaseI (see
Materials and Methods). The amount of nuclear extract is indicated above
each lane (in Ag). G + A is a Maxam and Gilbert (34) depurination of the
same fragment. Regions protected from DNaseI digestion are indicated by
lines; dotted lines show weak footprints. Arrows indicate DNaseI
hypersensitive sites. Numbers indicate the position of the protected
regions; their precise boundaries are indicated on Fig. 5. Footprints
observed with HeLa extracts are summarized on the left side of the gels,
whereas those observed with K562 and/or MEL extracts are summarized on the
right side.
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Fig. 2:
Gel mobility shift assays of various oligonucleotides with nuclear
extracts from HeLa (H), K562 (K), uninduced MEL (UM), induced MEL (IM) or T-
cells (T). Brackets in panel B indicate pairs of nuclear extracts made from
the same population of MEL cells before and after induction. The amount of
nuclear extract is indicated above each lane (in jig). The PBGD oligonucleo-
tide probes used contain the sequences which show protection from DNaseI
digestion on Fig. 1 (see text and Materials and Methods for details). A,
-180; B, -160; C, -130; D, -lOOCAC; E, -70; F, +45. Panels G and H
show the gel retardation patterns of oligonucleotides B and D from the human
f-globin enhancer, respectively. Panel I shows the gel retardation pattern
of oligonucleotide OCAC. Panel J shows the gel retardation patterns of
oligonucleotides c-fos Apl, SV40 Apl and chicken fi-globin enhancer region
II. Symbols indicate the different retarded bands discussed in the text:
triangles, NF-E1; double arrow-head, complex b3/c2; U, Apl; E, NF-E2;
diamonds, NF-U1; filled circles, CAC-binding proteins. The minor bands in
all panels are bindi ng artifacts because they cannot be competed. Other
(less reproducible) minor bands have not been studied in any detail.
Adenovirus NFI binding site and three API binding sites (see Materials and
Methods). The oligonucleotides A, B, C, D, fB-200 and,-120 all bind the
erythroid-specific protein NF-E1 in addition to a series of non-erythroid
proteins (14,15). The 0-150 oligonucleotide binds two non-tissue specific
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factors (15). One of these is CP1 which also binds to the ct-CAAT
oligonucleotide (18), while the other factor is NF1 as reported by Jones et
al. (19). The NFI complex shows different gel retardation patterns
depending on the assay conditions (not shown; see 18). Three
oligonucleotides with Apl consensus sequences were used: the first one
contains the c-fos-300 Api/PEA1 binding site with a single base change
increasing the affinity for the protein (20); the second contains the SV40
enhancer Apl binding site; the third contains the sequence of region II of
the chicken P-globin gene enhancer (21). This region shows an exact match
with the Apl consensus sequence and is protected from DNaseI digestion in
chicken erythrocyte extracts from day 9 of development. However, the
proteins were not further characterized (21,22).
Oligonucleotide -180 shows one strong DNA fragment mobility shift after
incubation with a nuclear extract from K562 or uninduced MEL cells (Fig.2A).
Two minor retarded bands appear together with this main band; they are
competed in the same way and thus are probably related to it. The same
pattern is observed with induced MEL extracts (not shown). Binding with a
HeLa nuclear extract shows a very weak band at the same position, as well as
another weak band of slower mobility. This second band co-migrates with a
complex seen with oligonucleotides B and C (b3/c2 in 14 and Fig. 2G) and is
competed by oligonucleotides B and C (not shown), suggesting that it is
similar to the b3/c2 complex. The major erythroid band is competed by all
fl-globin NF-E1 binding oligonucleotides (Fig. 3A). Since only C and D
(strong binding sites), but not A and B (weak binding sites) compete
efficiently, we conclude that this is a strong NF-E1 binding site. This
band is also competed by oligonucleotides -180, -70 and +45, the latter
giving only partial competition in the conditions used. In a HeLa extract,
the lower band is competed in the same way as in a MEL extract. Since this
has a slightly different mobility, it may represent the presence of a
protein related to NF-E1 in these cells.
Oligonucleotide -70 shows the same major gel retarded complex (Fig. 2E)
and competition profile (Fig. 3E) as the -180 region. This oligonucleotide
thus contains another strong NF-E1 binding site.
Oligonucleotide +45 gives rise to three retarded bands in K562 and MEL
extracts (Fig. 2F). The lower band co-migrates with the major bands of
oligonucleotides -180 and -70 and is present in far higher amounts in K562
and MEL extracts than in the HeLa extract. It is competed by all NF-El
binding oligonucleotides (Fig. 3F). In this case, oligonucleotide A, which
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Fig. 3:
Gel mobility shift assays in the presence of competitors. All
competitions shown were carried out using an uninduced MEL nuclear extract,
except the assays with the PBGD -160, chicken fi-globin and Apl probes
(panels B and J) which were carried out using an induced MEL extract. The
oligonucleotide probes are: A, -180; B, -160; C, -130; D, -IOOCAC; E,
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-70; F and G, +45; H, oligonucleotide C from the human f-globin enhancer;
I. eCAC; J, c-fos Apl, SV40 Apl and chicken fl-globin enhancer region II.
The competitors used (50ng per assay) are indicated above each lane. Panel
G shows a double competition experiment where oligonucleotide -70 (50ng) was
added together with other competitors. The amounts of nuclear extract used
are: Panels A, D, E, F, G, H: 5Ag; C,I: 10Lg; B,J: 15Ug. Symbols
indicate the different retarded bands as in Fig. 2.
is a rather weak NF-E1 binding site, appears to compete efficiently,
indicating that +45 is a weaker NF-E1 site than -180 and -70. The two upper
bands are competed by oligonucleotides +45 (itself), -100 (CAC box), -130,
,CAC and weakly by aCAAT. Their intensity increases when NF-E1 is competed
specifically, indicating that these factors and NF-E1 have overlapping
binding sites. In order to determine the precise nature of the upper bands,
we did a double competition experiment by first competing out NF-E1 and then
adding other oligonucleotides (Fig. 3G). Under these conditions, efficient
competition is only achieved with +45 itself, -100 CAC, -130 and ,BCAC. We
therefore conclude that the upper two bands represent CAC-binding proteins,
binding with rather low affinity to the +45 oligonucleotide. In a HeLa
extract the NF-E1 complex is not observed at +45, but the other complexes
seen in MEL extracts are present. Finally, no difference could be detected
in the bandshifting pattern of oligonucleotides -180, -70, +45 between
uninduced and induced MEL extracts (not shown).
Oligonucleotide -160, which contains an Apl consensus sequence, as well
as a sequence analogous to the -150 region of the human ,-globin promoter,
gives rise to several bands in gel retardation assays. Fig. 2B shows the
retarded bands obtained with three different HeLa extracts, T-cell, K562 and
uninduced MEL extracts and three pairs of uninduced and induced MEL extracts
which were prepared by different techniques (23,24). The slowest migrating
complex, which appears sharp in HeLa extracts, but is more diffuse in K562,
MEL and T-cell extracts (band U in Fig. 2B) is competed efficiently by the
c-fos Apl, SV40 Apl and chicken f-globin gene enhancer region II
oligonucleotides (Fig. 3B). All other oligonucleotides used in this study
were unable to compete, including fl-150 (not shown). A second, faster
migrating band is absent from the non-erythroid cell extracts (HeLa and T-
cells), but is present in the erythroid cell extracts (K562 and MEL),
showing that it is erythroid-specific (band E in Fig. 2B). It is competed
like the first band (Fig. 3B). In addition, mouse brain and adult liver
nuclear extracts yield only the upper retarded complex, whereas mouse foetal
liver (erythroid) nuclear extracts yield both complexes (not shown). This
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indicates that the same ubiquitous and erythroid-specific complexes are
found in non cultured cells. Bands with a similar mobility are also
observed with the c-fos Apl and SV40 Apl oligonucleotides, as well as with
the chicken P-globin enhancer region II (Fig. 2J). Moreover, competition
experiments (Fig. 3J) confirm that these complexes are identical to those
observed with the -160 probe. Therefore, we conclude that the Apl motif
accounts for the binding activity at -160 and that the Apl consensus
sequence is able to bind at least one erythroid-specific protein in addition
to the family of proteins already described in HeLa cells (17,25,26).
Finally, we have observed a quantitative variation between the
different -160 complexes in uninduced and induced MEL nuclear extracts (Fig.
2B). Interestingly, the ratio of intensity between the lower and upper
bands changes after induction of MEL cells for all three pairs of extracts
shown: the proportion of the lower band is higher after induction
(approximately three-fold). Although we cannot rule out the possibility
that, for example, growth conditions could be responsible for this
difference, it is striking that the erythroid-specific band becomes of equal
or greater intensity to the ubiquitous band after induction. To date, this
is the only description of a relative increase in a factor-binding during
MEL cell differentiation.
We propose to name the erythroid specific protein(s) which bind(s) in
addition to Apl to this oligonucleotide Nuclear Factor Erythroid 2 (NF-E2).
The c-fos Apl and SV40 Apl oligonucleotides each form additional but
different specific complexes (Fig. 2J), not involving the Apl consensus
sequence itself as they are not competed by other Apl oligonucleotides.
Interestingly, the upper complex formed with the SV40 Apl oligonucleotide is
competed efficiently by the PBGD -180 oligonucleotide (Fig. 3J). Since -180
binds the b3/c2 and NF-E1 proteins, this upper complex may be b3/c2. This
is confirmed by the efficient reciprocal competition of b3/c2 by the SV40
Apl oligonucleotide (not shown) and we therefore conclude that this upper
complex is identical to the b3/c2 complex. Comparison of the sequence of
oligonucleotides B and C from the P-globin 3' enhancer, SV40 Apl and PBGD
-180 (see Materials and Methods) reveals a consensus sequence: A/T N A/G
TAATNNN A/G. Methylation interference data (L. Wall et al., unpublished)
confirm that this sequence belongs to the b3/c2 binding site.
Oligonucleotide -130 yields four weak retarded bands (Fig. 2C) in all
extracts tested. No difference could be seen between uninduced and induced
MEL extracts (not shown). The first, third and fourth bands from the top of
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the gel are efficiently competed by -100 CAC, fCAC, +45 and -130 itself
(Fig. 3C). As these bands co-migrate with the complexes formed with the
PBGD -100 CAC and PCAC oligonucleotides, we conclude that -130 is a (weak)
binding site for CAC box proteins. (Note that the fourth band in Fig. 2C
co-migrates with an aspecific band often seen in our experiments). The
second band is competed by -130 and weakly by +45 (Fig. 3C); we have named
this ubiquitous factor NF-U1 (see below and Fig. 5).
The -100 PBGD CAC box is very homologous to the CAC box of the human ,B-
globin gene (,BCAC) and occurs at a similar position in this promoter. This
oligonucleotide forms three non-tissue specific complexes (Fig. 2D). These
complexes co-migrate with the three bands generated by the ,BCAC
oligonucleotide in MEL and K562 extracts. Competition assays in MEL (Fig.
3D) or HeLa (not shown) extracts show that all bands are competed by -100
CAC and fiCAC, and partially by +45, but not by -130, confirming that the
latter is a weak CAC protein binding site.
The reverse competitions (using non-PBGD probes and PBGD
oligonucleotide competitors) were also carried out (Fig. 3H,I,J). As
expected, the factors bound to a PCAC probe could be displaced efficiently
with a 200-fold excess of either PBGD CAC or,CAC oligonucleotides, and less
efficiently by -130 and +45 (Fig. 3I).
Analysis of the ,-globin CAC box (Spanopoulou, unpublished) has
recently shown that the top band represents low affinity binding by Spl and
that the bottom band represents high affinity binding by a CAC box specific
factor, in agreement with Xiao et al. (27) and Fromental et al (28). The
other (intermediate) bands are probably degradation products.
The NF-E1 complex formed with the fi-globin enhancer oligonucleotide C
(the strongest binding site in the,-globin enhancer) was competed
efficiently by -180 and -70 and mildly by +45, which is in agreement with
the previously noticed differences in the relative affinities of these sites
for NF-E1. In addition, oligonucleotide -180 was able to compete partially
the b3/c2 complex in HeLa and MEL extracts, indicating again that -180 is a
weak binding site for this factor (Fig. 3H).
Methylation interference assays
In order to characterize the binding sites of the different factors
more accurately, we analyzed them using a methylation interference assay
(29) (see Figs. 4 and 5).
The three NF-E1 binding sites show similar methylation interference
patterns to those obtained for NF-E1 sites in the human f-globin promoter
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VW*
Fig. 4:
Methylation interference experiment on both strands of the -160
oligonucleotide. The ubiquitous (U, from HeLa cells) and erythroid-specific
(E, from induced MEL cells) retarded bands as well as the free DNA band were
excised from a gel and treated as indicated in Materials and Methods. The
sequence of both strands is indicated. F, free DNA; B, bound DNA.
and 3' enhancer (14,15; Fig. 5). The binding sites are centred on a C/A
Py T/A ATC T/A Py consensus sequence and the weaker affinity of the +45
sequence could be explained by a T/A -> G mutation at the seventh
nucleotide, consistent with the loss in affinity of a T/A -> C mutation
generated at this position in vitro (L. Wall et al., unpublished results).
The three proteins which recognize the CAC box yield identical methylation
interference patterns (summarized in Fig. 5); this result was also obtained
for these same proteins binding to the P-globin proximal CAC box (15). The
other two CAC protein binding sites show comparable methylation interference
patterns: a stretch of consecutive purines on one strand, and 1 to 3
purines on the 5' end of the site on the other strand, interfere with
protein binding when they are methylated. Binding of the ubiquitous protein
which recognizes the -130 oligonucleotide (NF-U1, Fig. 3C) was impaired by
methylation of five purines on the non-coding strand around -130 (Fig. 5).
Comparison of the methylation interference data on -130 with the DNaseI
footprints (Fig. IA) shows that NF-U1 does not appear in the MEL footprints.
Gel retardation assays showed that this particular MEL extract contained a
lower amount of NF-U1 than the MEL extract used for Fig. 2C (not shown).
Finally, a methylation interference assay performed on the -160 probe
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Summary of the protein-DNA interactions on the PBGD erythroid specific
promoter in MEL or K562 nuclear extract. Thick lines indicate regions which
are protected from DNaseI digestion in the presence of extract. Dotted
lines indicate weak footprints. Arrows indicate DNaseI hypersensitive sites
created by factor-binding. Symbols indicate the nucleotides whose
methylation interfers strongly (filled symbols) or weakly (open symbols)
with the binding of the following factors in vitro: triangles, NF-E1;
squares, NF-E2; stars, Apl; diamonds, NF-Ul; circles, CAC-binding
proteins. Co-ordinates are relative to the transcription start site (+1).
yielded slightly different patterns for the Apl and NF-E2 proteins. Both
bind to a sequence centred on the TGACTCAG Apl consensus, but binding of the
erythroid-specific protein seems to be more sensitive to methylation of
three nucleotides on the downstream side, and less sensitive to methylation
of a G at -162 (Figs. 4 and 5). Therefore, it appears that the erythroid-
specific protein NF-E2 has a different sequence specificity compared to the
ubiquitous protein Apl. This is further confirmed by the fact that point
mutations within the -160 region show an altered affinity for either Apl or
NF-E2 in MEL nuclear extracts (not shown).
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Fig. 6:
Comparison of protein-DNA interactions on the human PBGD and f-globin
promoters. The ,-globin promoter has been described by deBoer et al. (15).
Proteins which compete for binding to overlapping sequences are shown above
each other. See Discussion for details. Numbers indicate promoter co-
ordinates relative to the transcription initiation site (+1).
DISCUSSION
Transcription of the globin genes and genes coding for enzymes of the
heme biosynthetic pathway increases during erythroid differentiation. It is
therefore probable that a common mechanism is responsible for this co-
ordinated regulation. Amongst the genes coding for enzymes of the heme
biosynthetic pathway, the porphobilinogen deaininease gene has an interesting
organization: it has two promoters, one of which is ubiquitously expressed
and the other one which is expressed in erythroid cells only (16). In
addition, this latter promoter shows structural homologies with the f-globin
promoter and both are induced during erythroid differentiation. The
analysis of the PBGD erythroid specific promoter is therefore important in
order to understand the mechanisms which are responsible for the inducible
erythroid specific expression and co-regulation of different sets of genes.
The results obtained in this work have shown that several protein
factors can bind to the PBGD erythroid-specific promoter in vitro. These
results can be summarized as follows (Figs. 5 and 6):
1) Previous analysis showed that similar sequences were present in
the PBGD and ,B-globin promoters (16), i.e. the CAC box and mutated TATA and
CAAT boxes. Indeed, no footprint or gel mobility shift (not shown) can be
observed with either the CAAT or the TATA analogue. However, the CAC box
forms the same complexes as observed with the fi-globin promoter, although
the relative affinities are different (see Fig. 2).
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2) Other ubiquitous motifs are present in the PBGD promoter.
Firstly, CAC binding proteins were also shown to bind to other sequences
with a lower affinity, namely a CTGCTGCCCCTG sequence around -120 and a
CGCCTCCCTCTA sequence around +45, which are considerably different to the
CAC consensus. Again, methylation interference showed that methylation of
purines on the non-coding strand was able to prevent binding.
Secondly, a ubiquitous factor (present in HeLa, K562 and MEL cells)
binds a sequence around -130. This factor, which we named NF-U1, has not
been identified either by competition (Fig. 3C), or by comparison with known
binding sites (30,19).
Thirdly, the PBGD promoter weakly binds the b3/c2 protein at -180.
This protein appears to bind to the human P-globin gene enhancer (regions B
and C) (14) and the SV40 enhancer (near the Apl binding site).
3) Several erythroid-specific binding sites were found:
Firstly, three motifs bind NF-E1, a protein which is present in foetal
and adult erythroid cells and was shown to bind multiple sites in the human
f-globin promoter and enhancer; this protein is very abundant in erythroid
cells (5,000-20,000 copies/cell) (14,15).
Secondly, a motif around -160 is able to bind different proteins in
non-erythroid and erythroid cells. An erythroid-specific factor (not
developmental-specific), appears in foetal liver, K562 and MEL, but not in
adult liver, brain, HeLa or T-cell nuclear extracts. This protein, which we
have called NF-E2, competes with at least one non-erythroid-specific complex
(Apl) and the ratio of erythroid versus non-erythroid protein binding to the
-160 sequence increases reproducibly after induction of MEL cells. The
functional role of these two factors is unknown and an analysis of the
contribution of each of them will require a detailed mutagenesis and
expression study.
Interestingly, the erythroid specific complex NF-E2 has a slightly
different binding sequence specificity compared to Apl, as revealed by
methylation interference (Figs. 4 and 5) and point mutagenesis experiments
(not shown). It appears, therefore, not to be Apl, but could belong to a
family of Apl-like proteins. In addition, we have shown that the same Apl
and NF-E2 complexes bind the chicken P-globin gene enhancer (region II) in
murine erythroid nuclear extracts. In chicken erythrocytes, a footprint
over this region was observed from day 9 of development, but the proteins
were not further characterized (21,22).
A comparison between the architecture of the PBGD and $-globin
promoters (Fig. 6 and ref.15) shows some interesting similarities and
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differences. The PBGD promoter clearly lacks a TATA or CAAT box motif (or
the corresponding factors binding), which may explain its lower level of
expression. However, it contains a conserved CAC box, as well as two weaker
CAC protein binding sites. It is not clear whether all the CAC protein
binding sites play a role in the function of the promoter. Clearly, the
-100 CAC site is the strong binding site and probably has a similar function
to the equivalent sequence in the fi-globin gene. Mutation of that sequence
leads to a 5-10-fold reduction in transcription of the $-globin gene in
vivo (31,32). Our preliminary expression experiments also show that
deletion of the -100 CAC box results in a drastic decrease in transcription
of the PBGD promoter (V. Mignotte et al., unpublished). This is presumably
due to a loss of co-operativity between factors, as such a role has recently
been described for a CAC box and a glucocorticoid responsible element in
the tryptophan oxygenase gene (33). Interestingly, in both the PBGD and f-
globin promoters, the CAC box appears to be close to one of the NF-E1
binding sites (Fig. 6); in addition, the chicken f,-globin gene enhancer
region III, which is close to the NF-E1 binding site IV, also contains a CAC
consensus sequence (21).
The erythroid specific PBGD and f,-globin promoters both contain
multiple binding sites for the erythroid specific factor NF-E1, which is
probably a positive acting factor (15).
Contrary to the f-globin gene, the PBGD gene does not bind CP1 in the
upstream part of the promoter which, in the case of f-globin, appears to be
involved in its induction (15). Instead, it binds NF-E2 and Apl at a
similar position, which suggests that NF-E2 may be a positive factor for the
induction of PBGD transcription. This would be in agreement with the
relative increase of NF-E2 binding over Apl binding which is observed during
MEL cell differentiation (Fig. 2B). NF-E2 and Apl do not appear to bind the
human P-globin 260bp promoter or minimal 3' enhancer (14,15 and our
competition assays), but binding of these factors outside these two
sequences is not ruled out.
Further detailed studies involving mutagenesis of the PBGD erythroid
specific promoter and purification and characterization of the factors are
in progress to enable us to understand the role of each regulatory region in
this promoter.
MATERIALS AND METHODS
The PBGD oligonucleotides contained the sequence of the following
regions, relative to the transcriptional start site (see Fig. 5): -180:
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base pairs -197 to -164; -160: -170 to -142; -130: -149 to -107; -100
CAC: -112 to -76; -70: -83 to -55; +45: +34 to +65, Sall cohesive ends
were added for future use. In addition, the sequence of non-PBGD
oligonucleotides is indicated in deBoer et al. (15) with the exception of
the c-fos Apl oligonucleotide, which is derived from the PK oligonucleotide
of Kryszke et al. (20): GAAACCTGCTGACTCAGATGTCCT, the SV40 Apl
oligonucleotide: CATCTCAATTAGTCAGCAACCAG and the chicken f-globin enhancer
region II oligonucleotide: TCCCCGAAGGAGCTGACTCATGCTAGCCCAGCAG. The
preparation of nuclear extracts, the footprinting and the gel shift assays
were carried out as previously described (15).
Methylation interference assays were carried out as follows:
50ng of single stranded oligonucleotide was 32P-labelled, precipitated
and dried (15). The DNA was re-dissolved, methylated (G+A) as described by
Maxam and Gilbert (34) (except that the salmon sperm DNA was omitted) and
annealed to its opposite strand partner. After a gel mobility shift assay,
the bands containing different complexes or free DNA were excised from the
gels. The radioactive DNA was electroeluted, then treated with NaOH to yield
a G greater than A pattern (35), allowing detection of interference by
methylated guanines and adenines, precipitated and loaded on 10% sequencing
gels.
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